Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEM/RZR vs SOF/VEL in Chronic Hepatitis C
NCT06868264Phase 3Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of bemnifosbuvir, ruzasvir in hepatitis C virus infection, sponsored by Atea Pharmaceuticals. Started Apr 2025; status: completed.
02
Drugs
bemnifosbuvirruzasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT06868264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868264.